Cargando…
Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells
JAK2-V617F plays a key role in the pathogenesis of myeloproliferative neoplasm. However, its inhibitor ruxolitinib has shown limited clinical efficacies because of the ruxolitinib-persistent proliferation of JAK2-V617F-positive cells. We here demonstrate that the USP9X inhibitor WP1130 or EOAI340214...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072561/ https://www.ncbi.nlm.nih.gov/pubmed/32050632 http://dx.doi.org/10.3390/cancers12020406 |
_version_ | 1783506435122921472 |
---|---|
author | Akiyama, Hiroki Umezawa, Yoshihiro Watanabe, Daisuke Okada, Keigo Ishida, Shinya Nogami, Ayako Miura, Osamu |
author_facet | Akiyama, Hiroki Umezawa, Yoshihiro Watanabe, Daisuke Okada, Keigo Ishida, Shinya Nogami, Ayako Miura, Osamu |
author_sort | Akiyama, Hiroki |
collection | PubMed |
description | JAK2-V617F plays a key role in the pathogenesis of myeloproliferative neoplasm. However, its inhibitor ruxolitinib has shown limited clinical efficacies because of the ruxolitinib-persistent proliferation of JAK2-V617F-positive cells. We here demonstrate that the USP9X inhibitor WP1130 or EOAI3402143 (G9) inhibited proliferation and induced apoptosis more efficiently in cells dependent on JAK2-V617F than on cytokine-activated JAK2. WP1130 preferentially downregulated activated and autophosphorylated JAK2-V617F by enhancing its K63-linked polyubiquitination and inducing its aggresomal translocation to block downstream signaling. Furthermore, JAK2-V617F associated physically with USP9X in leukemic HEL cells. Induction of apoptosis by inhibition of USP9X was mediated through the intrinsic mitochondria-mediated pathway, synergistically enhanced by BH3 mimetics, prevented by overexpression of Bcl-xL, and required oxidative stress to activate stress-related MAP kinases p38 and JNK as well as DNA damage responses in HEL cells. Although autophosphorylated JAK2-V617F was resistant to WP1130 in the ruxolitinib-persistent HEL-R cells, these cells expressed Bcl-2 and Bcl-xL at lower levels and showed an increased sensitivity to WP1130 as well as BH3 mimetics as compared with ruxolitinib-naive HEL cells. Thus, USP9X represents a promising target along with anti-apoptotic Bcl-2 family members for novel therapeutic strategies against JAK2-V617F-positive myeloproliferative neoplasms, particularly under the ruxolitinib persistence conditions. |
format | Online Article Text |
id | pubmed-7072561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70725612020-03-19 Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells Akiyama, Hiroki Umezawa, Yoshihiro Watanabe, Daisuke Okada, Keigo Ishida, Shinya Nogami, Ayako Miura, Osamu Cancers (Basel) Article JAK2-V617F plays a key role in the pathogenesis of myeloproliferative neoplasm. However, its inhibitor ruxolitinib has shown limited clinical efficacies because of the ruxolitinib-persistent proliferation of JAK2-V617F-positive cells. We here demonstrate that the USP9X inhibitor WP1130 or EOAI3402143 (G9) inhibited proliferation and induced apoptosis more efficiently in cells dependent on JAK2-V617F than on cytokine-activated JAK2. WP1130 preferentially downregulated activated and autophosphorylated JAK2-V617F by enhancing its K63-linked polyubiquitination and inducing its aggresomal translocation to block downstream signaling. Furthermore, JAK2-V617F associated physically with USP9X in leukemic HEL cells. Induction of apoptosis by inhibition of USP9X was mediated through the intrinsic mitochondria-mediated pathway, synergistically enhanced by BH3 mimetics, prevented by overexpression of Bcl-xL, and required oxidative stress to activate stress-related MAP kinases p38 and JNK as well as DNA damage responses in HEL cells. Although autophosphorylated JAK2-V617F was resistant to WP1130 in the ruxolitinib-persistent HEL-R cells, these cells expressed Bcl-2 and Bcl-xL at lower levels and showed an increased sensitivity to WP1130 as well as BH3 mimetics as compared with ruxolitinib-naive HEL cells. Thus, USP9X represents a promising target along with anti-apoptotic Bcl-2 family members for novel therapeutic strategies against JAK2-V617F-positive myeloproliferative neoplasms, particularly under the ruxolitinib persistence conditions. MDPI 2020-02-10 /pmc/articles/PMC7072561/ /pubmed/32050632 http://dx.doi.org/10.3390/cancers12020406 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Akiyama, Hiroki Umezawa, Yoshihiro Watanabe, Daisuke Okada, Keigo Ishida, Shinya Nogami, Ayako Miura, Osamu Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells |
title | Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells |
title_full | Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells |
title_fullStr | Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells |
title_full_unstemmed | Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells |
title_short | Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells |
title_sort | inhibition of usp9x downregulates jak2-v617f and induces apoptosis synergistically with bh3 mimetics preferentially in ruxolitinib-persistent jak2-v617f-positive leukemic cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072561/ https://www.ncbi.nlm.nih.gov/pubmed/32050632 http://dx.doi.org/10.3390/cancers12020406 |
work_keys_str_mv | AT akiyamahiroki inhibitionofusp9xdownregulatesjak2v617fandinducesapoptosissynergisticallywithbh3mimeticspreferentiallyinruxolitinibpersistentjak2v617fpositiveleukemiccells AT umezawayoshihiro inhibitionofusp9xdownregulatesjak2v617fandinducesapoptosissynergisticallywithbh3mimeticspreferentiallyinruxolitinibpersistentjak2v617fpositiveleukemiccells AT watanabedaisuke inhibitionofusp9xdownregulatesjak2v617fandinducesapoptosissynergisticallywithbh3mimeticspreferentiallyinruxolitinibpersistentjak2v617fpositiveleukemiccells AT okadakeigo inhibitionofusp9xdownregulatesjak2v617fandinducesapoptosissynergisticallywithbh3mimeticspreferentiallyinruxolitinibpersistentjak2v617fpositiveleukemiccells AT ishidashinya inhibitionofusp9xdownregulatesjak2v617fandinducesapoptosissynergisticallywithbh3mimeticspreferentiallyinruxolitinibpersistentjak2v617fpositiveleukemiccells AT nogamiayako inhibitionofusp9xdownregulatesjak2v617fandinducesapoptosissynergisticallywithbh3mimeticspreferentiallyinruxolitinibpersistentjak2v617fpositiveleukemiccells AT miuraosamu inhibitionofusp9xdownregulatesjak2v617fandinducesapoptosissynergisticallywithbh3mimeticspreferentiallyinruxolitinibpersistentjak2v617fpositiveleukemiccells |